06th week of 2013 patent applcation highlights part 29 |
Patent application number | Title | Published |
20130034494 | RADIOLABELED PROSTATE SPECIFIC MEMBRANE ANTIGEN INHIBITORS - Compounds according to Formula I and Formula II are potent inhibitors of PSMA activity: | 2013-02-07 |
20130034495 | ISOTOPOLOGUES OF 4-[9-(TETRAHYDRO-FURAN-3-YL)-8-(2,4,6-TRIFLUORO-PHENYLAMINO)-9H-PURIN-2-Y- LAMINO]-CYCLOHEXAN-1-OL - Provided herein are isotopologues of Compound 1, which are enriched with isotopes such as, for example, deuterium. Pharmaceutical compositions comprising the isotope-enriched compounds, and methods of using such compounds are also provided. | 2013-02-07 |
20130034496 | POSITRON EMISSION TOMOGRAPHY TRACER - The present invention relates to positron emission tomography tracers and methods of using these tracers. | 2013-02-07 |
20130034497 | IODINE-LABELED HOMOGLUTAMIC ACID AND GLUTAMIC ACID DERIVATIVES - This invention relates to derivatives of Iodine-labeled homoglutamic acids and glutamic acids and their analogues suitable for labeling or already labeled by Iodine, methods of preparing such compounds, compositions comprising such compounds, kits comprising such compounds or compositions and uses of such compounds, compositions or kits for diagnostic imaging or radiotherapy. | 2013-02-07 |
20130034498 | OPTICAL MICROLABELS: SHAPES AND REFLECTORS - Labels and methods of producing labels for use in clinical, analytical and pharmaceutical development assays are provided. Labels may comprise shape-encoded particles which may be coupled to ligands such as DNA, RNA and antibodies, where different shapes are used to identify which ligand(s) are present. Labels may also comprise reflectors, including retroreflectors and retroreflectors susceptible to analyte-dependent assembly for efficient homogeneous assays. | 2013-02-07 |
20130034499 | SGII AS A PROGNOSTIC MARKER IN CONDITIONS WHICH REQUIRE CRITICAL CARE - The present invention relates to methods for determining the prognosis of a condition which requires critical care, said methods comprising determining the level of SgII, or fragments thereof in a subject. The methods of the invention can also be used to determine whether an individual is suffering from a condition which requires critical care and determining the severity of a condition which requires critical care. | 2013-02-07 |
20130034500 | Cationic Steroid Antimicrobial Compositions and Methods of Use - The invention provides methods for decreasing or inhibiting herpesviridae (HV) infection or pathogenesis of a cell in vitro, ex vivo or in vivo, a symptom or pathology associated with a herpesviridae (HV) infection or pathogenesis in vitro, ex vivo or in vivo, or an adverse side effect of herpesviridae (HV) infection or pathogenesis in vitro, ex vivo or in vivo. In one embodiment, a method of the invention includes treating a subject with an invention compound (e.g., cationic steroid antimicrobial or CSA). | 2013-02-07 |
20130034501 | DIARYLHYDANTOIN COMPOUNDS - The present invention relates to diarylhydantoin compounds, including diarylthiohydantoins, and methods for synthesizing them and using them in the treatment of hormone lefiactory prostate cancer. | 2013-02-07 |
20130034502 | Color Changing Cosmetic - The present invention is a substance that allows users to monitor temperature changes and appearance cosmetically on the human body by a change in color of the applied substance. It is intended for direct application to the skin and hair. The range of colors can be adjusted depending on the demand for the specific product or desired effect. The product is meant to be a temporary solution to cosmetically visually show the users temperature or change how the user looks. The cosmetic substance can be applied in many different ways and its unique color changing characteristics can be used on many products. | 2013-02-07 |
20130034504 | COMPOUNDS HAVING MUSCARINIC RECEPTOR ANTAGONIST AND BETA2 ADRENERGIC RECEPTOR AGONIST ACTIVITY - Compounds of formula (I) act both as muscarinic receptor antagonists and beta2 adrenergic receptor agonists and are useful for treating and/or preventing broncho-obstructive and inflammatory diseases. | 2013-02-07 |
20130034505 | Cassia Derivatives - This invention related to a cationically and hydrophilically modified polygalactomannan having repeating units with an average D-mannosyl to D-galactosyl residue ratio of at least 5 to 1 and to compositions containing the same. A portion of the hydrogen atoms of hydroxyl groups situated on the mannosyl and galactosyl residues of the galactomannan are replaced with a hydrophilic and a cationic substituent. | 2013-02-07 |
20130034506 | Water-Soluble Surfactant Compositions Having Improved Taste - Treated surfactant composition containing a water-soluble surfactant and exhibiting improved taste, said composition comprising: a water-soluble surfactant selected from alkyl phosphate surfactants, alkyl phosphate ethoxylated surfactants, betaine surfactants, betaine ethoxylated surfactants, amine oxide surfactants, and mixtures thereof and water; wherein the composition further comprises: less than about 4%, by weight of the water-soluble surfactant, of total undesirable non-polar materials; less than about 2.5%, by weight of the water-soluble surfactant, of alcohols having a carbon chain length of greater than 4; less than about 1%, by weight of the water-soluble surfactant, of amine and amide materials; and less than about 1%, by weight of the water-soluble surfactant, undesirable non-polar materials selected from aldehydes, esters, ketones, and organic acids. Such compositions wherein the compositions have been subjected to liquid-liquid extraction processes. | 2013-02-07 |
20130034507 | Chlorine Dioxide Treatment for Biological Tissue - Methods, compositions, devices, and systems for administration to a biological tissue of a composition comprising a chlorine dioxide source are provided. | 2013-02-07 |
20130034508 | Process For Surfactant Taste And/Or Odor Improvement - Processes for improving the taste of water-soluble surfactants using liquid-liquid solvent extraction, said process comprising the steps of: providing a water-soluble surfactant composition in need of treatment wherein said water-soluble surfactant composition comprises a water-soluble surfactant and one or more undesirable non-polar materials; contacting said water-soluble surfactant composition with an extraction solvent and water to form an extraction mixture comprising an aqueous phase and a solvent phase; and separating the aqueous phase from the solvent phase; wherein the extraction solvent is selected from solvents having individual Hansen solubility parameters of a dispersion force component (δ | 2013-02-07 |
20130034509 | COSMETIC TREATMENT METHOD INVOLVING A COMPOUND CAPABLE OF CONDENSING IN SITU - The present invention relates to a method for the cosmetic treatment of the skin involving a compound, or set of compounds, capable of condensing in situ. | 2013-02-07 |
20130034510 | MELANIN MODIFICATION COMPOSITIONS AND METHODS OF USE - A method for the modification of melanin distribution, and the composition thereof to modify melanin distribution are disclosed. A method for the reduction of melanin distribution, and the composition thereof to reduce melanin distribution are disclosed. A representative composition comprises 4-ethoxybenzaldehyde and one or more additional active agents as well as a pharmaceutically acceptable carrier or excipient. Carriers and excipients may be formulated for topical administration. Compositions may also be formulated for transdermal administration. The compositions may be used for the prevention and treatment of pigmentation disorders, by way of non-limited example, post-inflammatory hyperpigmentation and others. The compositions may be used for lightening skin. | 2013-02-07 |
20130034511 | NOVEL COMPOUND - The invention relates to novel polyglycerol based UV-filters as well as to topical compositions comprising such novel polyglycerol based UV-filters. Furthermore, the invention relates to the use of such novel polyglycerol based UV-filters to enhance the solubility of butyl methoxydibenzoylmethane or bis-ethylhexyloxyphenol methoxyphenyl triazine in cosmetic oils. | 2013-02-07 |
20130034512 | EASILY APPLIABLE, STORAGE STABLE, RADIATION-CURABLE, PIGMENTED, ARTIFICIAL NAIL GEL COATINGS - A composition, method, and use of a UV curable, thixotropic, radiation curable, low viscosity gel is described. The composition is comprised of thixotropic additive(s) and in some cases dispersants for additional dispersion stability. The thixotropic pigmented gel has prolonged shelf life and long time storage at ambient conditions. It also contains negligible amounts of unreactive solvent. The thixotropic additive also changes the rheological properties of the gel, which allows the nail gel to be easily applied to nails at a lower viscosity due to shear thinning. | 2013-02-07 |
20130034513 | USE OF A COSMETIC COMPOSITION COMPRISING AT LEAST ONE FILM-FORMING ELASTOMERIC POLYMER FOR TREATING HUMAN PERSPIRATION - The present invention relates to the use of a cosmetic composition comprising, in a cosmetically acceptable medium, one or more nonionic, anionic, amphoteric or cationic film-forming elastomeric polymers, capable of giving, on drying of the said elastomeric polymer(s), at room temperature and at a relative humidity of 55%, a material with a mechanical profile defined by at least: a) a degree of elongation at break (ε) greater than or equal to 150%, b) an instantaneous recovery (R1) of greater than or equal to 75% after an elongation of 150%, c) a recovery at 300 seconds (R | 2013-02-07 |
20130034514 | HAIR TREATMENT PRODUCTS COMPRISING SPECIFIC POLYETHERS AND HAIR-FIXING POLYMERS - Hair treatment agents having in addition to at least one hair-setting polymer, at least one polyether of formula (I) | 2013-02-07 |
20130034515 | HAIR CARE COMPOSITIONS - This document provides methods and materials related to hair care. For example, hair care compositions containing one or more quaternized polysiloxanes, one or more zwitterionic surfactants, one or more anionic surfactants, one or more botanical compounds, one or more amino acids, one or more vitamins, or any combination thereof as well as methods for using such hair care compositions are provided. | 2013-02-07 |
20130034516 | USE OF THE MODIFIED POLYSACCHARIDES FOR HEPARIN NEUTRALIZATION - The subject of the invention is the use of cationically modified polysaccharides, except for chitosan, for direct neutralization of heparin in blood and physiological fluids in a mammal. Cationic modification of the polysaccharides is achieved using compound containing cationic ammonium groups and/or the polysaccharides are grafted with a polymer containing amine and/or ammonium groups. | 2013-02-07 |
20130034517 | TARGETED DRUG PHOSPHORYLCHOLINE POLYMER CONJUGATES - The present invention provides random copolymers containing phosphorylcholine and one or more functional agents, and methods of preparing such random copolymers. | 2013-02-07 |
20130034518 | Interleukin-12 P40 Variants with Improved Stability - Modified interleukin-12 (IL-12) p40 polypeptides are disclosed. The modified polypeptides have alterations in the IL-12p40 subunit to eliminate the protease site between positions Lys260 and Arg261. The modified IL-12p40 polypeptides according to the invention have improved stability compared to wild-type mature human IL-12p40 polypeptides. | 2013-02-07 |
20130034519 | ORGANIC COMPOUNDS AND THEIR USES - The present application describes organic compounds that are useful for the treatment, prevention and/or amelioration of human diseases. | 2013-02-07 |
20130034520 | Hepatitis C Virus Inhibitors - The present disclosure relates to compounds, compositions and methods for the treatment of hepatitis C virus (HCV) infection. Also disclosed are pharmaceutical compositions containing such compounds and methods for using these compounds in the treatment of HCV infection. | 2013-02-07 |
20130034521 | 1'-SUBSTITUTED CARBA-NUCLEOSIDE ANALOGS FOR ANTIVIRAL TREATMENT - Provided are pyrrolo[1,2-f][1,2,4]triazinyl, imidazo[1,5-f][1,2,4]triazinyl, imidazo[1,2-f][1,2,4]triazinyl, and [1,2,4]triazolo[4,3-f][1,2,4]triazinyl nucleosides, nucleoside phosphates and prodrugs thereof, wherein the 1′ position of the nucleoside sugar is substituted. The compounds, compositions, and methods provided are useful for the treatment of Flaviviridae virus infections, particularly hepatitis C infections. | 2013-02-07 |
20130034522 | THERAPIES FOR TREATING HEPATITIS C VIRUS INFECTION - A method of improving the pharmacokinetics of VX-222 in a patient infected with HCV comprises co-administering VX-222 and VX-950 to the patient. A method of treating a patient infected with HCV comprises administering VX-222 and VX-950 to the patient, wherein VX-222 is in an amount of about 20 mg to about 400 mg, and wherein VX-950 is in an amount of about 100 mg to about 1,500 mg. A method of treating a patient infected with HCV comprises administering a therapeutically effective amount of VX-222, wherein VX-222 is administered at an amount of about 20 mg to about 2,000 mg once a day. | 2013-02-07 |
20130034523 | USE OF SDF-1 TO MITIGATE SCAR FORMATION - The subject matter provided herein relates to method for inhibiting or mitigating scar formation in a wound of the skin, by increasing the concentration of SDF-1 in, or proximate to, the wound. As described herein SDF-1 protein or an SDF-1 expression vector can be administered to a wound or the area proximate a wound by providing a therapeutically effective amount of SDF-1 protein or an SDF-1 expression vector. | 2013-02-07 |
20130034524 | Non-Enzymatic Method for Harvesting Adipose-Derived Stromal Cells and Adipose-Derived Stem Cells from Fat and Lipo-Aspirate - The present disclosure relates generally to processes, devices and systems for separating and concentrating stem and stromal cells from adipose tissue using a combination of mechanical disruption and filtration-centrifugation to obtain a highly enriched population of stem cells. | 2013-02-07 |
20130034525 | BETA ISELETS-LIKE CELLS DERIVED FROM WHOLE BONE MARROW - The invention provides for methods of producing pancreatic precursor cells and insulin-producing cells from bone marrow. In various embodiments, bone marrow derived stem cells are differentiated into pancreatic precursor cells and insulin-producing cells. In various embodiments, bone marrow derived stem cells are artificially induced to express VEGF and/or PDX-1. These cells can be used to treat or ameliorate diabetes or symptoms of diabetes. | 2013-02-07 |
20130034526 | POPULATIONS OF PANCREATIC PROGENITOR CELLS AND METHODS OF ISOLATING AND USING SAME - A method of generating pancreatic progenitor cells is disclosed. The method comprises:
| 2013-02-07 |
20130034527 | MITOCHONDRIAL ENHANCEMENT OF CELLS - Certain embodiments disclosed herein include, but are not limited to, at least one of compositions, methods, devices, systems, kits, or products regarding rejuvenation or preservation of stem cells. Certain embodiments disclosed herein include, but are not limited to, methods of modifying stem cells, or methods of administering modified stem cells to at least one biological tissue. | 2013-02-07 |
20130034528 | NEW METHODS FOR ISOLATING TR1 CELLS - The present invention relates to methods for isolating Tr1 cells, resting Tr1 cells and/or activated Tr1 cells, to methods for enriching or depleting a cell population in Tr1 cells, resting Tr1 cells and/or activated Tr1 cells and to methods and kits for treating chronic inflammatory diseases, autoimmune diseases, allergic diseases, cancer and organ transplantation conditions. | 2013-02-07 |
20130034529 | NATURAL COMPOSITIONS AND METHODS OF PROMOTING WOUND HEALING - Compositions comprising honey, myrhh, and | 2013-02-07 |
20130034530 | Dietary Supplement Cognitive Support System - The present invention relates to a nutritional supplement composition, comprising a therapeutically effective amounts of Vitamin C, Vitamin D3, Thiamin, Riboflavin, Niacin, Vitamin B6, Folic acid, Vitamin B12, Pantothenic acid, Calcium, Magnesium, Zinc, Chromium, Sugar, Protein, Acetyl-L-Carnitine, Dimethylaminoethanol complex, Phosphatidylserine complex, L-Glutamine, N-Acetyl-L-Tyrosine, L-Phenylalanine, Taurine, Methionine, Valine, Isoleucine, 5 Hydroxytryptophan, L-Taurine, N-Acetyl-Tyrosine, N-Acetyl-L-Cysteine, Alpha Lipoic Acid, Alpha Glycerylphosphoricholine complex, Bacopa Monnieri extract, Gingko Biloba extract, Passion flower, Lemon Balm, Gotu Kola, Ashwagandha, Choline Bitartrate complex, Panax Ginseng extract, Turmeric, Organic freeze dried fruit juice blends (concord grape, red raspberry, pineapple, cranberry, acai, pomegranate, acerola cherry, bilberry, lingonberry, black currant, aronia, sour cherry, black raspberry), Organic freeze dried greens blends (barley grass, broccoli, beet, carrot, alfalfa, oat), and Protein digestive enzyme blends (Protease 4.5, peptidase, bromelain, protease 6.0, protease 3.0, L planatrum, B bifidum) in a mixture to provide optimal cognitive function. | 2013-02-07 |
20130034531 | USE OF PROTEASES FOR GLUTEN INTOLERANCE - The present technology relates to an enzyme composition. The enzyme composition may be used to treat gluten intolerant subjects, including suffering from non-Celiac gluten intolerance and/or non-Celiac gluten sensitivity. The enzyme composition may also be used to reduce gluten exposure in certain individuals. For example, the enzyme composition may also be used as a prophylactic to reduce exposure to gluten oligopeptides. | 2013-02-07 |
20130034532 | NANOZYMES, METHODS OF MAKING NANOZYMES, AND METHODS OF USING NANOZYMES - Embodiments of the present disclosure provides for nanozymes, methods of making nanozymes, methods of using nanozymes, and the like. | 2013-02-07 |
20130034533 | High Molecular Weight Derivatives of Vitamin K-Dependent Polypeptides - Modifications of vitamin K-dependent polypeptides that lead to enhanced protein function on a weight or molar basis and/or increase of protein lifetime in the circulation are described. Both objectives are important for using vitamin K-dependent polypeptides for pro- and anti-coagulation therapies, as well as for other uses in the circulation. | 2013-02-07 |
20130034534 | METHOD FOR TREATMENT OF PATIENTS WITH CYSTIC FIBROSIS - A method for treatment of patients with cystic fibrosis by providing an inhalable aerosol comprising a mucolytic compound (dornase alpha) administered into a patient's lungs according to a specific treatment protocol setting comprising a mucolytic drug containing aerosol having particles with a predetermined mass medial aerodynamic diameter (MMAD) delivered predominantly to a peripheral lungs using a nebulizing system able to administer said aerosol with overpressure and under controlled breathing conditions. | 2013-02-07 |
20130034535 | METHOD FOR TREATING OBESITY WITH ANTI-OBESITY FORMULATIONS AND OMEGA 3 FATTY ACIDS FOR THE REDUCTION OF BODY WEIGHT IN CARDIOVASCULAR DISEASE PATIENTS (CVD) AND DIABETICS - Combinations of one or more anti-obesity drugs with mixtures of an omega-3 fatty acid formulation containing about 90% or more omega 3 fatty acids by weight comprised of a combination of Eicosapentaenoic acid (EPA), Docosapentaenoic acid (DPA) and Docosahexaenoic acid (DHA) in a weight ratio of EPA:DHA of from 5.7 to 6.3, wherein the sum of the EPA, DHA and DPA comprise about 82% by weight of the total formulation and about 92% of the total omega 3 fatty acid content of the composition for the reduction of body weight in cardiovascular disease patients (CVD) and diabetics. | 2013-02-07 |
20130034536 | Bile Acid Recycling Inhibitors for Treatment of Pancreatitis - Provided herein are methods and compositions comprising bile acid transport inhibitors and/or enteroendocrine peptide enhancing agents and/or FXR agonists for the treatment of pancreatitis or prevention of pancreatitis. | 2013-02-07 |
20130034537 | SIMULTANEOUS CO-TREATMENT OF PHYSICAL AND MENTAL SYMPTOMS RELATED TO SEVERE MENTAL DISORDERS BY A SPECIALLY FERMENTED SOY FORMULATION (FSWW08) - A method of treating severe mental diseases and related disorders or conditions includes administering to a patient in need thereof an effective amount of a composition including isoflavones and Bowman Birk Inhibitory Factor (BBIF). Preferably, the composition is a fermented soy composition. Preferably, one first diagnoses a patient with a particular mental disease or disorder, and then prescribes the composition as a treatment for the particular mental disease or disorder. A patient is preferably given daily a dosage of 3-10 mg of isoflavones and 5-10 Cl (chymotrypsin inhibitor) of BBIF per kg of body weight, more preferably a dosage of 5-9 mg of isoflavones and 5-10 CCl of BBIF per kg of body weight, and most preferably a dosage of 5-10 mg of isoflavones and 5-10 CCl of BBIF per kg of body weight. Treatment preferably lasts 7 days-14 days, or until all symptoms disappear. | 2013-02-07 |
20130034538 | REVERSE HEXAGONAL MESOPHASES (HII) AND USES THEREOF - Reverse hexagonal mesophase (H | 2013-02-07 |
20130034539 | SR-BI AS A PREDICTOR OF HUMAN FEMALE INFERTILITY AND RESPONSIVENESS TO TREATMENT - Methods of diagnosis and treatment of diseases and disorders related to de novo synthesis of cholesterol, based on allelic variants of the scavenger receptor class B type I receptor, and kits for use therein. | 2013-02-07 |
20130034540 | Immune Gene Signatures in Cancer - This invention relates to methods for selecting a treatment, treating, and predicting survival time in subjects with cancer, such as colorectal cancer, based on tumor expression levels of chemokines, cytotoxic genes, and/or dendritic cell genes. | 2013-02-07 |
20130034541 | PHARMACEUTICAL COMPOSITIONS - A composition including lactoferrin and immunoglobulin, wherein the composition does not substantially include one or more of the following proteins: lactoperoxidase, lactoglobulin, albumin. | 2013-02-07 |
20130034542 | COLD TREATMENT - A use of a composition including lactoferrin and/or immunoglobulin for minimizing the severity of one or more symptoms associated with common cold and/or influenza. | 2013-02-07 |
20130034543 | MODULATING XRN1 - The present invention relates to a method for modulating miRNA, said method being characterized in that a modulator of XRN1 is used. Also provided are uses of said method for therapeutical purposes, reagents therefore, as well as screening methods. | 2013-02-07 |
20130034544 | METHODS FOR TREATING, DIAGNOSING, AND MONITORING LUPUS - Methods of identifying, diagnosing, and prognosing lupus, including certain subphenotypes of lupus, are provided, as well as methods of treating lupus, including certain subpopulations of patients. The methods provided are based on a set of alleles associated with systemic lupus erythematosus (SLE) risk loci including BLK, TNIP1, PRDM1, JAZF1, UHRF1BP1, IL1 O, IFIH1, CFB, CEC16A, IL12B and SH2B3 that contribute to SLE risk. Also provided are methods for identifying effective lupus therapeutic agents and predicting responsiveness to lupus therapeutic agents. | 2013-02-07 |
20130034545 | TREATMENT OF TRAUMATIC BRAIN INJURY USING ANTIBODIES TO LYSOPHOSPHATIDIC ACID - Methods are provided for treating traumatic brain injury (TBI) using antibodies that bind lysophosphatidic acid (LPA). Particularly preferred antibodies to LPA are monoclonal antibodies, including humanized monoclonal antibodies. In particular, the TBI may be blast-induced TBI (bTBI) such as commonly occurs in battlefield injuries. The treatment may include functional locomotor recovery. | 2013-02-07 |
20130034546 | Analyzing Copy Number Variation in the Detection of Cancer - The invention provides a method for determining copy number variations (CNV) of a sequence of interest in a test sample that comprises a mixture of nucleic acids that are known or are suspected to differ in the amount of one or more sequence of interest. The method comprises a statistical approach that accounts for accrued variability stemming from process-related, interchromosomal and inter-sequencing variability. The method is applicable to determining CNV of any fetal aneuploidy, and CNVs known or suspected to be associated with a variety of medical conditions. CNV that can be determined according to the method include trisomies and monosomies of any one or more of chromosomes 1-22, X and Y, other chromosomal polysomies, and deletions and/or duplications of segments of any one or more of the chromosomes, which can be detected by sequencing only once the nucleic acids of a test sample. | 2013-02-07 |
20130034547 | RELIABLE STABILIZATION OF N-LINKED POLYPEPTIDE NATIVE STATES WITH ENHANCED AROMATIC SEQUONS LOCATED IN POLYPEPTIDE TIGHT TURNS - A chimeric therapeutic polypeptide of a pre-existing therapeutic polypeptide is disclosed, as are a method of enhancing folded stabilization and a pharmaceutical composition of the glycosylated chimer. The pre-existing and chimeric polypeptides have substantially the same length, substantially the same amino acid residue sequence, and exhibit at least one tight turn containing a sequence of four to about seven amino acid residues in which at least two amino acid side chains extend on the same side of the tight turn and are within less than about 7 Å of each other. The chimeric therapeutic polypeptide has the sequon Aro-(Xxx)n-(Zzz)p-Asn-Yyy-Thr/Ser (SEQ ID NO:001) within that tight turn sequence such that the side chains of the Aro, Asn and Thr/Ser amino acid residues project on the same side of the turn and are within less than about 7 Å of each other. That sequon is absent from the pre-existing therapeutic polypeptide. | 2013-02-07 |
20130034548 | USE OF ERBB3 INHIBITORS IN THE TREATMENT OF TRIPLE NEGATIVE AND BASAL-LIKE BREAST CANCERS - Provided are methods of suppressing growth of triple negative breast tumors and basal-like breast tumors by contacting tumor cells with an ErbB3 inhibitor, e.g., an anti-ErbB3 antibody. Also provided are methods for treating triple negative breast cancer or basal-like breast cancer in a patient by administering to the patient an ErbB3 inhibitor, e.g., an anti-ErbB3 antibody. The treatment methods can further comprise selecting a patient having a triple negative breast cancer or basal-like breast cancer and then administering an ErbB3 inhibitor to the patient. The treatment methods also can further comprise administering at least one additional anti-cancer agent to the patient in combination with the ErbB3 inhibitor. | 2013-02-07 |
20130034549 | COMBINATION THERAPY FOR TREATING BREAST CANCER - The invention provides compositions and methods for treating breast cancer. Specifically, the invention relates to administering a Transforming Growth Factor beta (TGFβ) antagonist in combination with capecitabine and ixabepilone to treat breast cancer. | 2013-02-07 |
20130034550 | Sustained release drug delivery systems comprising a water soluble therapeutic agent and a release modifier - A biocompatible, sustained release intraocular drug delivery system comprising a protein or polynucleotide therapeutic agent, a polymeric carrier for the therapeutic agent and a long chain fatty alcohol release modifier. The biocompatible, sustained release intraocular drug delivery system can be used to treat an ocular condition. | 2013-02-07 |
20130034551 | Wnt Antagonists and Methods of Treatment and Screening - The present invention relates to compositions comprising Wnt antagonists and methods of treating Wnt-associated diseases and disorders, such as cancer, inducing differentiation, and reducing the frequency of cancer stem cells, as well as novel methods of screening for such Wnt antagonists. In particular, the invention discloses soluble FZD, SFRP and Ror receptors and their use. | 2013-02-07 |
20130034552 | TEMPERATURE SENSITIVE CONJUGATE COMPOSITIONS, AND USES RELATED THERETO - This disclosure relates to temperature sensitive conjugates, compositions, and uses related thereto. In certain embodiments, the disclosure relates to conjugate polymers comprising a) a temperature sensitive polymer and b) an antibody. Typically the antibody has an epitope to a platelet receptor. The antibody may be a single-chain antibody wherein the platelet receptor is GPIIb/IIIa, such as an anti-GPIIb/IIIa antibody. In certain embodiments, the antibody binds specifically to the activated conformation of GPIIb/IIIa, i.e., an activation-specific GPIIb/IIIa antibody. | 2013-02-07 |
20130034553 | Fusion Polypeptides Capable of Activating Receptors - A fusion polypeptide comprising (A) | 2013-02-07 |
20130034554 | ANTIBODIES TO IL-6 AND USE THEREOF - The present invention is directed to therapeutic methods using IL-6 antagonists such as an Ab1 antibody or antibody fragment having binding specificity for IL-6 to prevent or treat disease or to improve survivability or quality of life of a patient in need thereof. In preferred embodiments these patients will comprise those exhibiting (or at risk of developing) an elevated serum C-reactive protein level, reduced serum albumin level, elevated D-dimer or other coagulation cascade related protein(s), cachexia, fever, weakness and/or fatigue prior to treatment. The subject therapies also may include the administration of other actives such as chemotherapeutics, anti-coagulants, statins, and others. Additional preferred embodiments of the subject invention relate to therapeutic compositions and methods treating or preventing rheumatoid arthritis, especially subcutaneous and intravenous formulations and dosage regimens using IL-6 antagonists according to the invention, as well as methods for preventing or treating GVHD or leukemia relapse in subjects receiving transplanted cells, tissue or organs, use thereof in the treatment or prevention of mucositis, and use thereof to potentiate the cytotoxic, apoptotic, and anti-metastatic or anti-invasive effects of chemotherapeutics and radiation on cancers, especially cancers that have developed a resistance to radiation or chemotherapy, such as an EGFR inhibitor. | 2013-02-07 |
20130034555 | EPITHELIAL MEMBRANE PROTEIN 2 (EMP2) BINDING REAGENTS AND THEIR THERAPEUTIC USES IN OCULAR DISEASES - A method is disclosed for treating diseases or disorders of the eye involving undesired expression of vascular endothelial growth factor (VEGF) by administration of endothelial membrane protein 2 (EMP2) inhibitor. The present invention relates to the direct treatment of macular degeneration, particularly age-related macular degeneration (AMD), by administering an EMP2 inhibitor intraocularly or systemically. | 2013-02-07 |
20130034556 | FREE HEXASACCHARIDE ISOLATED FROM SEVERAL CAMPYLOBACTER SPECIES - An isolated or purified compound is provided, comprising A-GlcNAc[GlcNAc]-GalNAc-GalNAc-QuiNAc4NAc, wherein A is GlcNAc or Glc. There is further provided a vaccine based on such compound, having particular use to treat or prevent an infection caused by a | 2013-02-07 |
20130034557 | Cancer-Related Glycopeptide Epitopes, Antibodies And Methods Of Use - Cancer-associated O-glycopeptide combination epitopes derived from the VNTR of MUC1 are disclosed. Autoantibodies present in human sera target the combination epitopes and are reduced or absent in cancer patients. The epitopes are useful as therapeutic and immunoprophylactic cancer vaccines. Monoclonal antibodies directed against the epitopes are also useful as immunotherapeutics for treatment and prevention of cancer. Diagnostic methods using the epitopes and antibodies are also disclosed. | 2013-02-07 |
20130034558 | EPIDERMAL GROWTH FACTOR RECEPTOR VARIANT - Provided are a novel Epidermal growth factor receptor variant-EGFRvA protein, a polynucleotide encoding the EGFRvA protein and a method of preparing the EGFRvA protein via recombination technology. Also provided is a uses of the polynucleotide encoding the EGFRvA protein. The EGFRvA protein has a function of promoting tumor cell invasion or promoting tumor cell migration. | 2013-02-07 |
20130034559 | Targeted Binding Agents Against B7-H1 - Human monoclonal antibodies directed against B7-H1 and uses of these antibodies in diagnostics and for the treatment of diseases associated with the activity and/or expression of B7-H1 are disclosed. Additionally, hybridomas or other cell lines expressing such antibodies are disclosed | 2013-02-07 |
20130034560 | RECOMBINANT PROTEINS FOR USE IN VACCINE, ANTIBODIES AGAINST SAID PROTEINS, AND DIAGNOSTIC AND THERAPEUTIC METHODS INCLUDING THE SAME - The present invention relates to proteins and/or fragments and derivatives thereof and their use as vaccines and in biotechnological methods. The vaccines particularly include immunogenic proteins in | 2013-02-07 |
20130034561 | ISOLATED MAMMALIAN MONOCYTE CELL GENES; RELATED REAGENTS - Nucleic acids encoding various monocyte cell proteins from a primate, reagents related thereto, including specific antibodies, and purified proteins are described. Methods of using said reagents and related diagnostic kits are also provided. | 2013-02-07 |
20130034562 | SELECTIVE ANDROGEN RECEPTOR MODULATORS FOR TREATING DIABETES - This invention provides use of a SARM compound or a composition comprising the same in treating and preventing muscle wasting in patients with non-small cell lung cancer (NSCLC); treating pre-cachexia or early cachexia (preventing muscle wasting in a cancer patient); treating and preventing loss of physical function due to cancer or cancer therapy; increase of physical function; and increasing survival in a patient with NSCLC, wherein the patients are subjected to cancer therapy. | 2013-02-07 |
20130034563 | USE FOR PRODUCTION OF THERAPEUTIC AGENT OR PROPHYLACTIC AGENT FOR OSTEOARTHRITIS - Methods for treating or preventing diseases classified as any of grade 1 to 3 according to the ICRS classification of osteoarthritis, classified as grade 1 to 3 according to the Kellgren-Lawrence classification of osteoarthritis, or classified as grade 1 to 3 according to the Outerbridge classification of osteoarthritis, include administering to a subject in need thereof a therapeutically effective amount of treatment agents or preventive agents containing an anti-Fas IgM antibody as an active ingredient to alleviate osteoarthritis symptoms by inhibiting the production of cartilage matrix degrading enzymes and by increasing the production of cartilage matrix. | 2013-02-07 |
20130034564 | ANTI-RSV G PROTEIN ANTIBODIES - Individual monoclonal antibodies and fragments that bind a conserved epitope of the G protein of RSV and which are minimally immunogenic when administered to a human subject, are useful in treating RSV infections. | 2013-02-07 |
20130034565 | MOLECULES AND METHODS OF USING SAME FOR TREATING ErbB/ErbB LIGANDS ASSOCIATED DISEASES - A method of selecting a target for treatment of a hyperproliferative disease in a subject in need thereof is disclosed. The method comprising analyzing an amount and/or activity of at least one ErbB ligand in a biological sample from the subject, wherein an ErbB ligand which shows an up-regulated amount and/or activity compared to a non-hyperproliferative cell or tissue above a predetermined level is selected as a target for treatment of the hyperproliferative disease. Methods of treating hyperproliferative diseases, monoclonal antibodies and pharmaceutical compositions are also disclosed. | 2013-02-07 |
20130034566 | ANTI-CDH3 ANTIBODIES AND USES THEREOF - The present invention relates to anti-CDH3 antibodies, which can be labeled with a radioisotope. Moreover, the present invention provides methods and pharmaceutical compositions that comprise an anti-CDH3 antibody as an active ingredient. Since CDH3 is strongly expressed in pancreatic, lung, colon, prostate, breast, gastric or liver cancer cells, the present invention is useful in pancreatic, lung, colon, prostate, breast, gastric or liver cancer therapies. | 2013-02-07 |
20130034567 | PROTEIN MODULATORS - The present invention relates to modulators of the Neuregulin (NRG) family, particularly NRG1 and more particularly NRG1β, and most particularly NRG1β1. The present invention also relates to the use of such modulators to inhibit goblet cell hyperplasia and therefore also relates to the use of such modulators in the treatment or prevention of human diseases and disorders featuring pathological mucus production such as COPD, CF, chronic bronchitis and asthma. | 2013-02-07 |
20130034568 | METHODS OF TREATING OR PREVENTING PERIODONTITIS AND DISEASES ASSOCIATED WITH PERIODONTITIS - The present disclosure describes methods for preventing or treating periodontitis or diseases associated with periodontitis. The present disclosure also describes methods of screening for compounds that can be used to prevent or treat periodontitis or diseases associated with periodontitis. | 2013-02-07 |
20130034569 | IL-18 RECEPTOR ANTIGEN BINDING PROTEINS - Provided herein are IL-18 receptor antigen binding proteins and polynucleotides encoding the same. Expression vectors and host cells comprising the same for production of the antigen binding proteins are also provided. In addition, provided are compositions and methods for diagnosing and treating diseases mediated by IL-18 receptor. | 2013-02-07 |
20130034570 | METHODS AND COMPOSITIONS FOR MODULATING PROSTASIN - The invention provides methods and compositions related to modulating prostasin. | 2013-02-07 |
20130034571 | METHODS FOR INDUCING IN VIVO TOLERANCE - The present invention encompasses methods for inducing in vivo tolerance to a foreign tissue. | 2013-02-07 |
20130034572 | COMPOSITIONS AND METHODS FOR BRAIN DELIVERY OF ANALGESIC PEPTIDES - The present invention relates to non-invasive brain delivery technology for centrally-acting analgesic peptides. Specifically, the invention is directed to compounds comprising an antibody or fragment thereof capable of transmigrating across the blood brain barrier (BBB) and an analgesic peptide. Compositions and methods of using the compounds or compositions are also provided. | 2013-02-07 |
20130034573 | VACCINE COMPOSITIONS - The present disclosure relates to vaccine compositions, particularly KLH-peptide conjugates, and methods of making such compositions. The present disclosure further relates to methods of reducing abnormal cell growth using the composistions described herein. | 2013-02-07 |
20130034574 | MODIFIED MELK PEPTIDES AND VACCINES CONTAINING THE SAME - Isolated peptides composed of the amino acid sequence of the modified MELK epitope peptide or immunologically active fragments thereof that bind to HLA antigens and have higher cytotoxic T lymphocyte (CTL) inducibility than that of the wild type MELK epitope peptide and thus are suitable for use in the context of cancer immunotherapy or endometriosis immunotherapy, more particularly cancer or endometriosis vaccines are described herein. The present invention further provides peptides that include one, two, or several amino acid insertions, substitutions or additions to the aforementioned peptides or fragments, but yet retain the requisite cytotoxic T cell inducibility. Further provided are nucleic acids encoding any of these aforementioned peptides as well as pharmaceutical substances and compositions including any of the aforementioned peptides or nucleic acids. The peptides, nucleic acids, pharmaceutical substances and compositions of this invention find particular utility in the treatment of cancers, tumors, and endometriosis. | 2013-02-07 |
20130034575 | METHOD FOR IDENTIFICATION, ISOLATION AND PRODUCTION OF ANTIGENS TO A SPECIFIC PATHOGEN - Described is a method for identification, isolation and production of hyperimmune serum-reactive antigens from a specific pathogen, a tumor, an allergen or a tissue or host prone to auto-immunity, said antigens being suited for use in a vaccine for a given type of animal or for humans, which is characterized by the following steps: providing an antibody preparation, providing at least one expression library, identifying antigens which bind, screening the identified antigens, identifying the hyperimmune serum-reactive antigen portion of said identified antigens and which hyperimmune serum-reactive antigens bind to a relevant portion of said individual antibody optionally isolating said hyperimmune serum-reactive antigens and producing said hyperimmune serum-reactive antigens by chemical or recombinant methods. | 2013-02-07 |
20130034576 | NOVEL ADENOVIRUS ISOLATED FROM TITI MONKEYS - Provided is a Titi Monkey Adenovirus (TMAdV) that can infect both human and non-human primates. Further provided are nucleic acid sequences, proteins, expression vectors and host cells, anti-TMAdV antibodies, vaccines, compositions, methods of detecting TMAdV, methods for assaying for anti-TMAdV compounds, and methods for treating or preventing a TMAdV infection. | 2013-02-07 |
20130034577 | Methods and Compositions for Vaccination Comprising Nucleic Acid and/or Polypeptide Sequences of Chlamydia - The instant invention relates to antigens and nucleic acids encoding such antigens obtainable by screening a | 2013-02-07 |
20130034578 | RECOMBINANT MULTIMERIC INFLUENZA PROTEINS - The invention relates to immunogenic compositions comprising recombinant multimeric influenza proteins or parts thereof fused to a streptavidin affinity tag, preferably recombinant trimeric influenza virus hemagglutinin and/or recombinant tetrameric influenza virus neuraminidase, or vectors comprising nucleic acid sequences encoding such influenza proteins. The inventions further relate to methods for the preparation of such immunogenic compositions and uses thereof and methods for eliciting an immune response in an individual. | 2013-02-07 |
20130034579 | IMMUNOGENIC COMPOSITIONS AND RELATED METHODS - This disclosure relates to adjuvants for use in immunogenic compositions comprising at least one antigen and an aluminum compound comprising hydroxyl groups that has been treated with phosphate, carboxylate, carbonate, sulfate diphosphonate or a mixture of two or more of these compounds and methods of using these compositions for preventing and treating diseases are also provided. | 2013-02-07 |
20130034580 | NOVEL FORMULATIONS WHICH STABILIZE AND INHIBIT PRECIPITATION OF IMMUNOGENIC COMPOSITIONS - The present invention addresses an ongoing need in the art to improve the stability of immunogenic compositions such as polysaccharide-protein conjugates and protein immunogens. The invention broadly relates to novel formulations which stabilize and inhibit precipitation of immunogenic compositions. More particularly, the invention described hereinafter, addresses a need in the art for formulations which stabilize and inhibit particulate formation (e.g., aggregation, precipitation) of immunogenic compositions which are processed, developed, formulated, manufactured and/or stored in container means such as fermentors, bioreactors, vials, flasks, bags, syringes, rubber stoppers, tubing and the like. | 2013-02-07 |
20130034581 | GENETICALLY ENGINEERED SWINE INFLUENZA VIRUS AND USES THEREOF - The present invention relates, in general, to attenuated swine influenza viruses having an impaired ability to antagonize the cellular interferon (IFN) response, and the use of such attenuated viruses in vaccine and pharmaceutical formulations. In particular, the invention relates to attenuated swine influenza viruses having modifications to a swine NS1 gene that diminish or eliminate the ability of the NS1 gene product to antagonize the cellular IFN response. These viruses replicate in vivo, but demonstrate decreased replication, virulence and increased attenuation, and therefore are well suited for use in live virus vaccines, and pharmaceutical formulations. | 2013-02-07 |
20130034582 | REVERSE GENETICS METHODS FOR VIRUS RESCUE - A method for rescuing a virus by reverse genetics is provided in which cells are added after transfection. | 2013-02-07 |
20130034583 | COMPOSITIONS, METHODS AND USES FOR EXPRESSION OF ENTEROBACTERIUM-ASSOCIATED PEPTIDES - Embodiments of the present invention generally disclose methods, compositions and uses for generating and expressing enterobacterial-associated peptides. In some embodiments, enterobacterial-associated peptides include, but are not limited to plague-associated peptides. In certain embodiments, methods generally relate to making and using compositions of constructs including, but not limited to, attenuated or modified vaccinia virus vectors expressing enterobacterial-associated peptides. In other embodiments, vaccine compositions are reported of use in a subject. | 2013-02-07 |
20130034584 | AGENT FOR USE IN THE TOPICAL OR LOCAL TREATMENT OF CERVICAL DYSPLASIAS - The invention relates to an agent for treating cervical dysplasias, comprising a recombinant, genetically modified E1-deleted adenovirus replication defective in non-HPV infected cells, which is suitable for local external application in the region of the portio and the cervix uteri. | 2013-02-07 |
20130034585 | Bovine Herpes Virus Vaccine With Multiple Mutations - A BHV-1 mutant virus has been made that incorporates into a single virus two or more deletions in one or more of three genes—glycoprotein N, glycoprotein E and Us9. Specifically, a BHV-1 U | 2013-02-07 |
20130034586 | AVIRULENT ONCOLYTIC HERPES SIMPLEX VIRUS STRAINS ENGINEERED TO COUNTER THE INNATE HOST RESPONSE - The present invention relates to an avirulent, oncolytic herpes simplex virus modified from a wild-type herpes simplex virus so that both γ | 2013-02-07 |
20130034588 | CHLAMYDIA PNEUMONIAE ASSOCIATED CHRONIC INTRAOCULAR DISORDERS AND TREATMENT THEREOF - Infection by | 2013-02-07 |
20130034589 | pH-SENSITIVE NANOPARTICLES FOR ORAL INSULIN DELIVERY - The present invention discloses the pH-sensitive nanoparticles composed of pH-sensitive polymer, hydrophobic material, internal stabilizer, external stabilizer content and insulin drug. The present invention also includes a method for preparation of pH-sensitive nanoparticles, in particular, a multiple emulsions solvent evaporation method. The pH-sensitive nanoparticles of the present invention show good pH-sensitive property with 100-300 nanometer particle size. Significant decrease in blood glucose level is observed in streptozotocin (STZ)-induced diabetic rats and the bioavailability of insulin is more than 10% after oral administration of the insulin-loaded pH-sensitive nanoparticles. | 2013-02-07 |
20130034590 | Delivery of Hydrophilic Drugs - Compositions comprising a lipophilic derivative of a hydrophilic drug and an amphiphile compound for use in therapy of the human or animal body are provided. Methods of medical treatment, wherein a composition according to the invention is administered to a human or animal body also form part of the invention. It is preferred that the drug is delivered to the brain. | 2013-02-07 |
20130034591 | NOVEL COMPOUNDS AND COMPOSITIONS FOR TARGETING CANCER STEM CELLS - The invention provides naphthofuran compounds, polymorphs of naphthofuran compounds, naphthofuran compounds in particle form, purified compositions that contain one or more naphthofuran compounds, purified compositions that contain one or more naphthofuran compounds in particle form, methods of producing these naphthofuran compounds, polymorphs, purified compositions and/or particle forms, and methods of using these naphthofuran compounds, polymorphs, purified compositions and/or particle forms to treat subjects in need thereof. | 2013-02-07 |
20130034592 | HYDROGEL - A hydrogel composed of a polyanionic polysaccharide derivative having a hydrophobic group introduced by covalent bonding and a salt solution with a salt concentration of 50 mM or more and 200 mM or less, the hydrogel having an aggregate structure with an average particle diameter of 100 to 2000 nm in the diluted solution, as well as a method for manufacturing the hydrogel comprising the steps of preparing a mixture containing a polyanionic polysaccharide derivative having a hydrophobic group introduced and a salt solution with a salt concentration of 50 mM or more and 200 mM or less and subjecting the mixture to heat treatment. The hydrogel of the present invention has a long-term stability and may be filtered using a porous filter having a pore diameter of 5 μm or more. | 2013-02-07 |
20130034593 | Method for Making Medical Devices Having Antimicrobial Coatings Thereon - The present invention provides a method for preparing a medical device, preferably a contact lens, having an antimicrobial metal-containing LbL coating on a medical device, wherein the antimicrobial metal-containing LbL coating comprises at least one layer of a negatively charged polyionic material having —COOAg groups and/or silver nanoparticles formed by reducing Ag | 2013-02-07 |
20130034594 | FIBERS CONTAINING FERRATES AND METHODS - A fiber containing ferrate, which comprises (1) one or more ferrate compounds, wherein the ferrate compound is selected from a group consisting of a metal ferrate(V) compound, metal ferrate(VI) compound, and a mixture thereof; and (2) one or more nonaqueous polymers. Also, methods are disclosed that make and/or use the fibers. | 2013-02-07 |
20130034595 | Local administration of gallium compositions to treat pain - Provided are methods of treating pain, including neuropathic pain, in human and veterinary individuals. These methods employ locally administrable pharmaceutical gallium compositions, including pharmaceutical gallium compositions suitable for administration to the skin and mucous membranes. The compositions comprise pharmaceutically acceptable gallium compounds, such as gallium maltolate or gallium nitrate, together with pharmaceutically acceptable carriers suitable for local administration, including those suitable for topical administration. The administration of such compositions provides relief from pain, itching, allodynia, hyperalgesia, and related symptoms. | 2013-02-07 |